Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063899
Chunk: 147

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 147
---
 it can quickly begin working with them, if necessary. At the time of this filing all other reagents DiamiR uses are commonly available
through multiple vendors on similar terms.

From time to time, DiamiR
also may purchase other reagents used in its tests and services from sole-source suppliers. While it may develop alternate sourcing strategies
for these materials and vendors, DiamiR cannot be certain whether these strategies will be effective, or the alternative sources will
be available in a timely manner. If these suppliers can no longer provide DiamiR with the supplies, DiamiR needs to perform its tests
and services, if the materials do not meet its quality specifications, or if DiamiR cannot obtain acceptable substitute materials, an
interruption in test processing and services could occur. Any such interruption may directly impact DiamiR’s revenue and cause it
to incur higher costs.

If DiamiR cannot enter into and maintain new clinical collaborations, its efforts to commercialize CogniMIR and its development of other products could be delayed.

DiamiR currently has several
ongoing collaborations with highly regarded academic institutions in the NDs field. DiamiR’s success in the future may depend in
part on its ability to enter into agreements with other leading institutions in the NDs field. In the process of seeking clinical collaborations
in the future DiamiR expects to engage in discussions with third parties, which may or may not lead to collaborations.

If DiamiR’s clinical tests do not perform as expected in its validation studies, it may not be able to achieve widespread market adoption among physicians, which would cause its operating results, reputation, and business to suffer.

There is no guarantee that
the accuracy and reproducibility DiamiR has demonstrated to date will continue in its planned clinical validation studies. As a result,
the failure of its products to perform as expected would significantly impair its operating results and its reputation. DiamiR may be
subject to legal claims arising from any defects or errors in its clinical services tests.

<div align='center'>69</div>

DiamiR’s ability to commercialize the diagnostic products that it develops is dependent on its relationships with laboratory services providers and support of its products.

DiamiR relies on third-party
providers to draw the donor blood samples and prepare plasma in accordance with its protocol. The Company’s business will suffer
if these service providers do not support CogniMIR or the other products that it may develop. A lack of acceptance of